|
|
| | 9alpha,11alpha-Dihydroxy-15-oxo-2,3,4,5-tetranor-prostan-1,20-dioic acid Basic information |
| Product Name: | 9alpha,11alpha-Dihydroxy-15-oxo-2,3,4,5-tetranor-prostan-1,20-dioic acid | | Synonyms: | TETRANOR-PGFM;TETRANOR PROSTAGLANDIN F METABOLITE;tetranor-PGFM Lipid Maps MS Standard;IGRHJCFWWOQYQE-SYQHCUMBSA-N;Cyclopentaneoctanoic acid, 2-(2-carboxyethyl)-3,5-dihydroxy-ε-oxo-, (1R,2R,3S,5R)-;9alpha,11alpha-Dihydroxy-15-oxo-2,3,4,5-tetranor-prostan-1,20-dioic acid | | CAS: | 23109-94-6 | | MF: | C16H26O7 | | MW: | 330.37 | | EINECS: | | | Product Categories: | | | Mol File: | 23109-94-6.mol |  |
| | 9alpha,11alpha-Dihydroxy-15-oxo-2,3,4,5-tetranor-prostan-1,20-dioic acid Chemical Properties |
| solubility | DMF: >100 mg/ml (from PGF2a); DMSO: >100 mg/ml (from PGF2a); Ethanol: >100 mg/ml (from PGF2a); PBS pH 7.2: >10 mg/ml (from PGF2a) |
| | 9alpha,11alpha-Dihydroxy-15-oxo-2,3,4,5-tetranor-prostan-1,20-dioic acid Usage And Synthesis |
| Description | tetranor-PGFM is the major urinary metabolite of PGF2α. Normal healthy females excrete 7-13 μg of tetranor-PGFM per day compared to 11-59 μg/24 hours for healthy males. In pregnant females, tetranor-PGFM levels in the urine are 2 to 5-fold higher and diminish to pre-pregnancy levels soon after labor. | | Uses | tetranor-PGFM is the major urinary metabolite of Dinoprost (HY-12956)[1]. | | Definition | ChEBI: 2,3,4,5-tetranor-prostaglandin FM is a prostanoid that is prostaglandin E2-UM in which the oxo group at position 9 has been reduced to the corresponding alcohol (alpha-configuration). It has a role as a metabolite. It is a prostanoid, an oxo dicarboxylic acid, a secondary alcohol and a ketone. | | References | [1] Granstrm E, et al. The structure of a urinary metabolite of prostaglandin F2a in man. J Am Chem Soc. 1969 Jun 4;91(12):3398-400. DOI:10.1021/ja01040a067 |
| | 9alpha,11alpha-Dihydroxy-15-oxo-2,3,4,5-tetranor-prostan-1,20-dioic acid Preparation Products And Raw materials |
|